Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹387 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹61 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Solara delivered its strongest quarter in eight quarters, with revenue of ₹392 crore (up 12% QoQ) and EBITDA of ₹61 crore (up 65% QoQ), driven by the base business which operates at 26% EBITDA margins and 54% gross margins. The base business continues to gain momentum through new customer wins and capacity utilization improvements, with 30% spare capacity available. Ibuprofen remains a drag with negative EBITDA, but management has appointed bankers to evaluate strategic options, expecting resolution in H1 FY27. The company targets becoming debt-free by FY29 and plans 4-5 DMF filings annually, though R&D benefits will only materialize from FY29 onwards. Key risk: Ibuprofen losses could persist if strategic options are delayed or unfavorable.
Colored figures show movement against the previous available record.
Guidance to track
- Bankers appointed to evaluate strategic options for ibuprofen business; process expected to conclude in H1 FY27.
- Management aims to make Solara debt-free (including working capital) by FY29.
- Company plans to file 4-5 Drug Master Files annually, with first filed in April 2026.
Risks flagged
- Ibuprofen recorded negative EBITDA again; strategic options may not yield favorable outcome, prolonging losses.
- Despite ₹200 crore R&D spend over 4-5 years, no new profitable product launched; new DMFs will only commercialize from FY29.
- Vizag site mothballed since 2024 incurs ₹12-15 crore annual maintenance cost with no revenue.
- Top 15-20 products contribute 75-80% of base business revenue; loss of any key customer could impact performance.
Key quotes
- Our business has delivered the highest revenue, gross margins and EBITDA in the previous eight quarters.
- We have an internal target of making Solara debt free by FY29.
- We are not backward integrated by any means. We source the IBA from third party.
Research modules